Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 506

1.

Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.

Virgo P, Denning-Kendall PA, Erickson-Miller CL, Singha S, Evely R, Hows JM, Freeman SD.

Br J Haematol. 2003 Nov;123(3):420-30.

PMID:
14617000
3.

Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.

Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P.

Eur J Clin Invest. 2007 Jan;37(1):73-82.

PMID:
17181570
4.

Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.

Nguyen DH, Ball ED, Varki A.

Exp Hematol. 2006 Jun;34(6):728-35.

PMID:
16728277
5.

Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells.

Gaipa G, Coustan-Smith E, Todisco E, Maglia O, Biondi A, Campana D.

Haematologica. 2002 Apr;87(4):347-56.

6.

Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33.

Cornish AL, Freeman S, Forbes G, Ni J, Zhang M, Cepeda M, Gentz R, Augustus M, Carter KC, Crocker PR.

Blood. 1998 Sep 15;92(6):2123-32.

8.

Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia.

Ross JF, Wang H, Behm FG, Mathew P, Wu M, Booth R, Ratnam M.

Cancer. 1999 Jan 15;85(2):348-57.

PMID:
10023702
9.

Enhanced myeloid specificity of CD117 compared with CD13 and CD33.

Nomdedéu JF, Mateu R, Altès A, Llorente A, Rio C, Estivill C, López O, Ubeda J, Rubiol E.

Leuk Res. 1999 Apr;23(4):341-7.

PMID:
10229319
10.
11.

Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow.

Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA.

Blood. 1991 Jul 1;78(1):30-7.

12.

Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia.

Bernstein ID, Singer JW, Smith FO, Andrews RG, Flowers DA, Petersens J, Steinmann L, Najfeld V, Savage D, Fruchtman S, et al.

Blood. 1992 Apr 1;79(7):1811-6.

14.

Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows.

Venditti A, Del Poeta G, Stasi R, De Fabriitis P, Coppetelli U, Bruno A, Simone MD, Papa G.

Haematologica. 1993 Nov-Dec;78(6):359-63.

PMID:
7513673
15.
17.

CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase.

Martín-Henao GA, Quiroga R, Sureda A, García J.

Am J Hematol. 1999 Jul;61(3):178-86.

18.

Surface marker expression in acute myeloid leukaemia at first relapse.

Thomas X, Campos L, Archimbaud E, Shi ZH, Treille-Ritouet D, Anglaret B, Fiere D.

Br J Haematol. 1992 May;81(1):40-4.

PMID:
1381608
19.

C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.

Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MA, Visser TJ, Bijl N, Geuijen CA, Marissen WE, Radosevic K, Throsby M, Schuurhuis GJ, Ossenkoppele GJ, de Kruif J, Goudsmit J, Kruisbeek AM.

Cancer Res. 2004 Nov 15;64(22):8443-50.

20.

Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia.

Mehrotra B, George TI, Kavanau K, Avet-Loiseau H, Moore D 2nd, Willman CL, Slovak ML, Atwater S, Head DR, Pallavicini MG.

Blood. 1995 Aug 1;86(3):1139-47.

Supplemental Content

Support Center